Day One shares jump 20% as brain tumor drug shows promise in mid-term study

Hospital of Medical Sciences: Confident black female neurologist, neurologist, neurosurgeon, looking at TV screen with brain image taken with MRI scanner, thinking about method treat sick patients.  save


Biopharmaceuticals day one (NASDAQ:DAWN) report data from the ongoing phase 2 trial of tovorafenib for the treatment of recurrent or progressive childhood low-grade glioma (pLGG).

The primary goal of the study, named FIREFLY-1, was the overall response rate (ORR) and the company is evaluating tovorafenib once a week.

Source by [author_name]


News7h: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button